BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us
Archives
  • September 2022
  • August 2022
  • July 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us
Subscribe

Browsing Tag

Cel-Sci Corporation

5 posts

Cel-Sci Corporation (NYSE American: CVM) is a biotechnology company that researches drugs for the treatment of cancer, autoimmune, and infectious diseases through the development of immunotherapy products.

Cel-Sci’s main product is Multikine, an immunotherapeutic agent that stimulates the body’s immune system. Multikine recently completed Phase III trials with the FDA. The therapeutic is also known as Leukocyte Interleukin Injection (LI). Multikine was in Phase II testing of patients with head and neck cancer during the early 2000s, showing that it had the ability to reduce tumor growth.

In 2007, the US FDA cleared Phase 3 trials for Multikine and it was designated an orphan drug to be used in neoadjuvant squamous cell carcinoma of the head and neck.

Official Website

CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022

Biotech NewsCEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022

  • BioTech Health X
  • September 14, 2022
CEL-SCI recently presented its Phase 3 data at ESMO 2022, which revealed that Neoadjuvant Multikine achieved groundbreaking tumor…
0 Shares
0
0
0
0
0
0
0
Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

Biotech NewsMerck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

  • BioTech Health X
  • July 20, 2022
Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…
0 Shares
0
0
0
0
0
0
0
EF Hutton Initiates Coverage of Cel-Sci CVM with 17 Price Target Ahead of Rumored News

Biotech NewsEF Hutton Initiates Coverage of Cel-Sci (CVM) with $17 Price Target Ahead of Rumored News

  • BioTech Health X
  • August 2, 2022
Tim Moore, CFA an Analyst at EF Hutton has recently published a report citing the opportunities for growth…
0 Shares
0
0
0
0
0
0
0
Exclusive Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future

BioTech CEO InterviewsExclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future

  • Jak Thomson
  • September 7, 2021
About Cel-Sci Corporation Cel-Sci Corporation is a publicly traded biotechnology business which develops, manufactures, and markets treatments focused…
1 Shares
1
0
0
0
0
0
0
Cel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head Neck Patients in Phase 3 Trial

Biotech NewsCel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head & Neck Patients in Phase 3 Trial

  • BioTech Health X
  • June 28, 2021
Data Shows Significant Overall Survival Benefit for Cancer Patients with Multikine Treatment Regimen Followed by Surgery & Radiotherapy…
0 Shares
0
0
0
0
0
0
0
BioTech Health X
3K
257
1
135
0
121
© BioTech Health X - 2021 - All Rights Reserved
  • Our Contributors
  • List of Modern Life Science Technologies
  • Contact Us

Subscribe For
BioTech Health X
Updates

Back to top